ANDROGEL (testosterone) by Besins Healthcare is androgen receptor agonists [moa]. First approved in 2000.
Drug data last refreshed 5h ago · AI intelligence enriched 3d ago
AndroGel is a transdermal testosterone gel approved in 2000 for hormone replacement therapy in men with testosterone deficiency. It works as an androgen receptor agonist to restore physiological testosterone levels. The product is indicated for hypogonadism and related testosterone deficiency states.
Product approaching loss of exclusivity with modest Medicare utilization signals a maturing brand requiring defensive strategy and potential team right-sizing.
Androgen Receptor Agonists
Androgen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Puberty, Testosterone, and Brain Development
Worked on ANDROGEL at Besins Healthcare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moAndroGel offers career exposure in a mature hormone replacement product navigating competitive pressure and LOE dynamics. Roles emphasize managed care negotiation, market defense, and sales execution rather than innovation or expansion.